Table 2.
ASR (95% CI) (directly standardised to the European Standard population) per 1 000 000 population by ethnic group, for all cancers and by diagnostic group, 0–29 years, Yorkshire, 1998–2009
| Ethnic classification and group | All cancers | Leukaemia | Lymphoma | CNS tumours | ||||
| ASR | (95% CI) | ASR | (95% CI) | ASR | (95% CI) | ASR | (95% CI) | |
| HES | ||||||||
| White | 154.0 | (148.5 to 159.4) | 32.5 | (30.0 to 35.1) | 28.4 | (26.1 to 30.7) | 29.1 | (26.7 to 31.5) |
| South Asian | 137.6 | (120.6 to 154.6) | 27.5 | (19.9 to 35.2) | 29.7 | (21.8 to 37.5) | 21.2 | (14.5 to 27.8) |
| Other | 203.6 | (173.6 to 233.6) | 25.6 | (14.9 to 36.3) | 41.2 | (27.9 to 54.6) | 38.4 | (25.2 to 51.5) |
| Onomap | ||||||||
| White | 174.2 | (168.4 to 180.0) | 34.7 | (32.1 to 37.4) | 32.6 | (30.2 to 35.1) | 31.0 | (28.6 to 33.4) |
| South Asian | 154.3 | (136.3 to 172.3) | 29.1 | (21.3 to 37.0) | 38.6 | (29.6 to 47.6) | 19.9 | (13.5 to 26.4) |
| Other | 189.9 | (160.9 to 218.9) | 37.4 | (24.4 to 50.4) | 31.0 | (19.5 to 42.5) | 36.2 | (23.5 to 49.0) |
| CHP | ||||||||
| White | 171.9 | (166.1 to 177.6) | 34.5 | (31.8 to 37.1) | 32.4 | (29.9 to 34.8) | 30.6 | (28.2 to 33.0) |
| South Asian | 162.5 | (144.1 to 181.0) | 34.6 | (26.0 to 43.1) | 35.7 | (27.1 to 44.3) | 21.2 | (14.5 to 27.8) |
| Other | 241.4 | (208.8 to 274.0) | 33.6 | (21.3 to 45.8) | 47.7 | (33.4 to 62.1) | 44.0 | (30.0 to 58.0) |
| COP | ||||||||
| White | 174.3 | (168.5 to 180.1) | 34.8 | (32.1 to 37.4) | 32.6 | (30.2 to 35.1) | 31.0 | (28.6 to 33.4) |
| South Asian | 186.5 | (166.8 to 206.3) | 36.3 | (27.5 to 45.0) | 44.5 | (34.9 to 54.2) | 23.9 | (16.8 to 30.9) |
| Other | 135.1 | (110.8 to 159.4) | 23.2 | (13.0 to 33.4) | 22.9 | (13.1 to 32.8) | 29.1 | (17.6 to 40.5) |
ASR, age standardised rate; CHP, ‘Combined HES priority’; COP, ‘Combined Onomap priority’; HES, Hospital Episode Statistics; CNS, central nervous system.